Ampio Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Ampio Pharmaceuticals, Inc. holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 6 Nice Classification classes. The owner is based in Englewood, CO.
373 Inverness Parkway, Suite 200
Englewood, CO 80112
Showing of trademarks Trademarks
Trademark Classifications
Ampio Pharmaceuticals, Inc.'s trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Education; providing of training; entertainment; sporting and cultural activities
Legal services; security services for the protection of property and individuals
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Ampio Pharmaceuticals, Inc. have?
Ampio Pharmaceuticals, Inc. has 16 U.S. trademarks filed with the USPTO.
What trademark classes does Ampio Pharmaceuticals, Inc. file in?
Ampio Pharmaceuticals, Inc. files trademarks across 6 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 41 (Education & Entertainment), Class 45 (Legal & Security Services), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What is Ampio Pharmaceuticals, Inc.'s trademark registration success rate?
Ampio Pharmaceuticals, Inc. has a 0% trademark registration rate, with 0 out of 16 resolved applications resulting in successful registration. Currently, 0 applications are pending review.